Skip to content

The Safety of ahSC in Chronic SCI With Rehabilitation

The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02354625
Enrollment
8
Registered
2015-02-03
Start date
2015-01-31
Completion date
2019-08-12
Last updated
2019-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraplegia, Quadriplegia, Spinal Cord Injury, Tetraplegia

Keywords

Schwann cells

Brief summary

The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) transplantation in participants with chronic SCI. This trial design is phase I, open label, unblinded, non-randomized, and non-placebo controlled multiple injury cohorts.

Detailed description

For humans with chronic SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of ahSC. In addition spinal cord cavitation may be reduced, and neural sprouting and plasticity may be enhanced via neurotrophic effects. In this trial, subjects will receive fitness conditioning and rehabilitation prior to transplantation in order to validate the stability of their neurological baseline and enhance their ability to undergo surgery with few complications. They will also receive fitness conditioning and rehabilitation post-transplantation to maintain health and promote neuronal activity and potential neuroplasticity. Trial enrollment will target 2 cohorts. The first cohort will be thoracic (T) level 2-12 ASIA Impairment Scale (AIS) grade A, B, or C (n = up to 4), the second cohort will be cervical (C) level 5 through T1 AIS A, B, or C (n = up to 6). Two (2) participants with AIS grade A will be enrolled prior to enrolling a participant with AIS B or C, applicable to both cohorts. Participants will be monitored throughout a 6 month post-transplantation evaluation period for occurrence of AEs (acute, delayed, and/or cumulative), as well as for changes in clinical status and neurological status. Safety and efficacy assessments will be performed at weeks 1 and 2 post-transplantation and months 2 and 6 post-transplantation.

Interventions

Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.

Sponsors

The Miami Project to Cure Paralysis
CollaboratorOTHER
W. Dalton Dietrich
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Persons with traumatic SCI that occurred a minimum of 12 months prior to enrollment; 2. Between the ages of 18 and 65 at last birthday; 3. SCI between spinal levels C5-T12 as defined by the most caudal level of intact motor and sensory function on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI); 4. ASIA Impairment Scale (AIS) grade A, B, or C at time of enrollment; 5. Lesion length less than or equal to 3 cm and lesion volume less than or equal to 2 cc, as approximated by MRI.

Exclusion criteria

1. Persons unable to safely undergo an MRI; 2. Persons with penetrating injury of the spinal cord or complete transection of the cord, as identified by MRI; 3. Persons with severe, uncorrected post-injury spinal deformity and/or spinal cord inadequately decompressed; 4. Persons with a cavity structure that would preclude successful transplantation, as identified by MRI; 5. Persons with syringomyelia - defined as patients with progressively enlarging cysts on T2 weighted images with associated neurological decline; 6. Persons with pre-existing conditions that would preclude satisfactory sural nerve harvest; 7. Intolerance to functional electrical stimulation of muscles; 8. Exercise induced abnormalities; 9. Range of motion of the upper or lower extremities outside functional limits for targeted fitness and rehabilitation activities; 10. Evidence of bone or joint pathology that adversely influences participation in the fitness and rehabilitation activities; 11. Fracture, dislocation, or extremity instruments (implanted or external) that adversely influences participation in the fitness and rehabilitation activities; 12. Unhealed pressure ulcer; 13. History of documented seizures, stroke, brain tumor, serious head injury, or any other intracranial problem that could increase the risk of seizures during motor evoked potentials testing; 14. Pregnant women or a positive pregnancy test in those women with reproductive potential prior to enrollment; 15. Presence of disease that might interfere with participant safety, compliance, or evaluation of the condition under study; 16. Body Mass Index (BMI) ≥ 35; 17. History of active substance abuse; 18. Persons who are current participants in any interventional trial; 19. Persons with a history of prior intrathecal or intraspinal cell therapy for SCI; 20. Persons allergic to gentamicin; 21. Persons who test positive for HIV or Hepatitis B or C virus; 22. Persons with lab values significantly outside of the upper and lower limits; 23. Persons who can independently ambulate.

Design outcomes

Primary

MeasureTime frame
International Standards of Neurological Classification of Spinal Cord InjuryChange from Baseline at 6 months
Magnetic Resonance Imaging of spinal cordChange from Baseline at 6 months
Neuropathic Pain Symptoms InventoryChange from Baseline at 6 months
ISCI Basic Pain dataset version2Change from Baseline at 6 months
Pain DiagramChange from Baseline at 6 months
Quantitative Sensory TestingChange from Baseline at 6 months

Secondary

MeasureTime frame
Timed Up and GoChange from Baseline at 6 months
Timed Stair ClimbChange from Baseline at 6 months
Capabilities of Upper Extremity QuestionnaireChange from Baseline at 6 months
ISCI Upper Extremity Basic datasetChange from Baseline at 6 months
ISCI Basic Bowel datasetChange from Baseline at 6 months
ISCI Basic Lower Urinary Tract datasetChange from Baseline at 6 months
ISCI Basic Male and Female Sexual Function datasetsChange from Baseline at 6 months
ISCI Quality of Life datasetChange from Baseline at 6 months
Sympathetic Skin ResponseChange from Baseline at 6 months
Somatosensory Evoked PotentialsChange from Baseline at 6 months
1-Repetition MaximumChange from Baseline at 6 months
Head-up TiltChange from Baseline at 6 months
Guy Farrar Subject Global Impression of ChangeChange from Baseline at 6 months
Modified Ashworth ScaleChange from Baseline at 6 months
Pendulum TestChange from Baseline at 6 months
Spinal Cord Assessment Tool for Spastic reflexesChange from Baseline at 6 months
Motor Evoked PotentialsChange from Baseline at 6 months
Graded Strength TestChange from Baseline at 6 months
Spinal Cord Independence Measure IIIChange from Baseline at 6 months
SCI-Functional Index Computer Adaptive TestingChange from Baseline at 6 months
10-Meter Walk TestChange from Baseline at 6 months
2-Minute Walk TestChange from Baseline at 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026